Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus

New England Journal of Medicine

Volumn 338, Issue 13, 1998, Pages 867-872

  Inzucchi, Silvio E ^a   Maggs, David G ^a   Spollett, Geralyn R ^a   Page, Stephanie L ^a   Rife, Frances S ^a   Walton, Veronika ^a   Shulman, Gerald I ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; METFORMIN; TROGLITAZONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; CHROMANS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0032568257     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199803263381303     Document Type: Article

References (29)

1. DeFronzo RA. The triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988;37:667-87.
2. Ashcroft FM. Mechanisms of the glycaemic effects of sulfonylureas. Horm Metab Res 1996;28:456-63.
3. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-4.
4. Fery F, Plat L, Balasse EO. Effects of metformin on the pathways of glucose utilization after oral glucose in non-insulin-dependent diabetes mellitus patients. Metabolism 1997;46:227-33.
5. Dornan TL, Heller SR, Peck GM, Tattersall RB. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care 1991;14:342-4.
6. DeFronzo RA, Goodman AM, Multiccnter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541-9.
7. Haupt E, Knick B, Koschinsky T, Liebermeister H, Schneider J, Hirche H. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabetes Metab 1991;17:224-31.
8. Hermann LS, Scherstén B, Bitzén P-O., Kjellström T, Lingärde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. Diabetes Care 1994;17:1100-9.
9. Toeller M. Alpha-glucosidase inhibitors in diabetes: efficacy in NIDDM subjects. Eur J Clin Invest 1994;24:Suppl 3:31-5.
10. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992;15:193-203.
11. O'Rourke CM, Davis JA, Saltiel AR, Cornicelli JA. Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus. Metabolism 1997;46:192-8.
12. Lee M-K, Miles PD, Khoursheed M, Gao K-M, Moossa AR, Olefsky JM. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 1995;43:1435-9.
13. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 1990;39:1056-62.
14. Troglitazone Study Group. The metabolic effects of troglitazone in non-insulin dependent diabetes. Diabetes 1997;46:Suppl 1:149A. abstract.
15. Kumar S, Boulton A, Beck-Nielsen H, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996;39:701-9.
16. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996;19:151-6.
17. Valiquette T, Huang S, Whitcomb R. Effects of troglitazone monotherapy in patients with NIDDM: a 6-month multicenter study. Diabetes 1997;46:Suppl 1:43A. abstract.
18. Iwamoto I, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effect of combination therapy of troglitazone and sulphonylureas in patients with type II diabetes who were poorly controlled by sulphonylurea therapy alone. Diabet Med 1996;13:365-70.
19. Ghazzi M, Radke-Mitchell L, Venable T, Troglitazone Study Group, Whitcomb R. Troglitazone improves glycemic control in patients with type II diabetes who are not optimally controlled on sulfonylurea. Diabetes 1997;46:Suppl 1:44A. abstract.
20. Raskin P, Graveline JF. Efficacy of troglitazone in combination with insulin in NIDDM. Diabetes 1997;46:Suppl 1:44A. abstract.
21. National Diabetes Data Group, Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57.
22. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E233.
23. Radioactive and stable isotope tracers in biomedicine. In: Wolfe R. Principles and practice of kinetic analysis. New York: Wiley-Liss, 1992:283-315.
24. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus: a 13C nuclear magnetic resonance study. J Clin Invest 1992;90:1323-7.
25. Chen YD, Swislocki AL, Jeng CY, Juang JH, Reaven GM. Effect of time on measurement of hepatic glucose production. J Clin Endocrinol Metab 1988;67:1084-8.
26. Sheu WH, Jeng CY, Fuh MM, Chen YD, Reaven GM. Effect of glipizide treatment on response to an infused glucose load in patients with NIDDM. Diabetes Care 1995;18:1582-7.
27. Vestergaard H, Weinreb JE, Rosen AS, et al. Sulfonylurea therapy improves glucose disposal without changing skeletal muscle GLUT4 levels in noninsulin-dependent diabetes mellitus subjects: a longitudinal study. J Clin Endocrinol Metab 1995;80:270-5.
28. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510-5.
29. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-9.